文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-FAPI放射性配体治疗:实体瘤中的新兴前景与临床希望:综合综述

[177Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review.
PubMed 文献 · Semin Nucl Med · 2025-07-03

本综述系统汇总[177Lu]Lu-FAPI靶向成纤维细胞活化蛋白(FAP)的放射性配体治疗在实体瘤中的现有临床证据,涵盖可用制剂、疗效、安全性、进展与挑战。初步研究显示其作为有效且相对安全诊疗一体化药物具有前景,联合治疗策略尤具优势。作者指出仍需更大规模、良好对照的临床研究以确立长期疗效与安全性。

要点

  • FAP在多种实体瘤的癌相关成纤维细胞中高表达,为[177Lu]Lu-FAPI提供治疗靶点。
  • 初步研究显示[177Lu]Lu-FAPI是有效且相对安全的诊疗一体化药物,联合治疗尤具优势。
  • 作者指出仍需更大规模、良好对照的临床研究以确立其长期疗效与安全性。

核心结论

  • [177Lu]Lu-FAPI作为有效且相对安全的诊疗一体化药物显示出可观前景,在联合治疗策略中尤具优势。
  • 作者指出仍需更大规模、良好对照的临床研究以确立其长期疗效与安全性。
  • 本综述强调[177Lu]Lu-FAPI在肿瘤诊疗中日益显现的作用,与个体化肿瘤策略的相关性不断增强,并呼吁进一步研究以完善其临床整合。

研究设计与样本

  • 本综述综合现有关于[177Lu]Lu-FAPI放射性配体治疗的临床证据,涵盖可用制剂、疗效、安全性、近期进展、挑战及在不同肿瘤类型中的新兴应用。
  • 迄今已有越来越多的初步研究探索[177Lu]Lu-FAPI在肿瘤学中的治疗潜力,多项正在进行的临床试验正在招募患者。

主要发现

  • [177Lu]Lu-FAPI在多种实体瘤中显示出作为有效且相对安全诊疗一体化药物的可观前景。
  • [177Lu]Lu-FAPI在联合治疗策略中具有特殊优势。

关键数值与推荐

  • FAP在广谱实体瘤的癌相关成纤维细胞(CAF)中高表达,为新型放射性药物提供治疗靶点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出仍需更大规模、良好对照的临床研究以确立其长期疗效与安全性。
  • 原文提到尽管存在当前局限性,但未具体列出局限性条目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[177Lu]Lu-FAPI, a novel and innovative radioligand targeting fibroblast activation protein (FAP), has rapidly emerged as a powerful therapeutic strategy for difficult-to-treat solid malignancies. FAP is highly expressed in cancer-associated fibroblasts (CAFs) across a broad spectrum of solid malignancies, thereby providing a valuable therapeutic target for novel radiopharmaceuticals. To date, a growing body of preliminary studies has explored the therapeutic potential of [177Lu]Lu-FAPI in oncology, with numerous ongoing clinical trials currently recruiting patients to substantiate its evolving prospects. This comprehensive review critically synthesizes current clinical evidence on [177Lu]Lu-FAPI radioligand therapy (RLT), outlining its available formulations, therapeutic efficacy, safety profile, recent advancements, challenges, and emerging applications across diverse tumor types. [177Lu]Lu-FAPI has shown considerable promise as an effective and relatively safe theranostic agent, with particular advantages in combination therapy approaches. Nevertheless, larger, well-controlled clinical studies are essential to establish its long-term efficacy and safety profile. Despite current limitations, this review underscores the emerging role of [177Lu]Lu-FAPI in oncological care, with growing relevance to personalized oncology strategies, and calls for further investigation to refine its clinical integration and maximize patient-specific outcomes.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Al-Ibraheem A, Abdlkadir AS, Ruzzeh S, et al. [177Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review. Semin Nucl Med. 2025. PMID: 40615277. doi:10.1053/j.semnuclmed.2025.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。